CLEVELAND--(BUSINESS WIRE)--ChanTest has developed a new stem cell-derived human cardiomyocyte (SC-hCM) action potential assay for improved cardiac risk evaluation of drug candidates in pre-clinical development. On Thursday, February 11 at 11:00 a.m. EST the company will host a free webinar to explain the advantages in sensitivity and cost of the new assay as compared to conventional non-human Purkinje fiber assays (PF).
